Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

February 24, 2021

Avoiding Lost-in-Translation with Submission Terminology

In a previous post, I discussed the importance of proper use of CDISC Controlled Terminology (CDISC CT) in SDTM....

Read article

October 28, 2020

When your ADaM package is not traceable back to SDTM

About three years ago, Cytel was helping a sponsor on a project where I had to conduct surveillance of some CRO...

Read article

April 27, 2020

Highlights from the 2020 Virtual CDISC EU Interchange - Part 2

In the first part of this two-parts blog, I speak about how the European CDISC Committee (E3C) together with CDISC...

Read article

April 24, 2020

Highlights from the 2020 Virtual CDISC EU Interchange by Angelo Tinazzi

In early March, when countries around the world started implementing lockdowns, the European CDISC Committee (E3C)...

Read article